A. E. Lang and A. M. Lozano, Parkinson's Disease, New England Journal of Medicine, vol.339, issue.16, pp.1130-1143, 1998.

J. W. Langston, The parkinson's complex: Parkinsonism is just the tip of the iceberg, Annals of Neurology, vol.59, issue.4, pp.591-596, 2006.

W. Dauer and S. Przedborski, Parkinson's Disease, Neuron, vol.39, issue.6, pp.889-909, 2003.

J. Bové, C. Zhou, V. Jackson-lewis, J. Taylor, Y. Chu et al., Proteasome inhibition and Parkinson's disease modeling, Annals of Neurology, vol.60, issue.2, pp.260-264, 2006.

P. P. Michel, E. C. Hirsch, and S. Hunot, Understanding Dopaminergic Cell Death Pathways in Parkinson Disease, Neuron, vol.90, issue.4, pp.675-691, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01348875

A. J. Espay, L. V. Kalia, Z. Gan-or, C. H. Williams-gray, P. L. Bedard et al., Disease modification and biomarker development in Parkinson disease, Neurology, vol.94, issue.11, pp.481-494, 2020.

D. G. Hernandez, X. Reed, and A. B. Singleton, Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance, Journal of Neurochemistry, vol.139, issue.1, pp.59-74, 2016.

K. J. Billingsley, S. Bandres-ciga, S. Saez-atienzar, and A. B. Singleton, Genetic risk factors in Parkinson?s disease, Cell and Tissue Research, vol.373, issue.1, pp.9-20, 2018.

A. Singleton and J. Hardy, The Evolution of Genetics: Alzheimer?s and Parkinson?s Diseases, Neuron, vol.90, issue.6, pp.1154-1163, 2016.

S. B. Larsen, Z. Hanss, and R. Krüger, The genetic architecture of mitochondrial dysfunction in Parkinson?s disease, Cell and Tissue Research, vol.373, issue.1, pp.21-37, 2018.

T. A. Manolio, F. S. Collins, N. J. Cox, D. B. Goldstein, L. A. Hindorff et al., Finding the missing heritability of complex diseases, Nature, vol.461, issue.7265, pp.747-753, 2009.

A. Elbaz, L. Carcaillon, S. Kab, and F. Moisan, Epidemiology of Parkinson's disease, Revue Neurologique, vol.172, issue.1, pp.14-26, 2016.

A. Elbaz, J. Clavel, P. J. Rathouz, F. Moisan, J. Galanaud et al., Professional exposure to pesticides and Parkinson disease, Annals of Neurology, vol.66, issue.4, pp.494-504, 2009.

C. M. Tanner, G. W. Ross, S. A. Jewell, R. A. Hauser, J. Jankovic et al., Occupation and Risk of Parkinsonism, Archives of Neurology, vol.66, issue.9, pp.1106-1113, 2009.

G. Van-maele-fabry, P. Hoet, F. Vilain, and D. Lison, Occupational exposure to pesticides and Parkinson's disease: A systematic review and meta-analysis of cohort studies, Environment International, vol.46, pp.30-43, 2012.

F. J. Vingerhoets, B. J. Snow, J. W. Tetrud, J. W. Langston, M. Schulzer et al., Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions, Annals of Neurology, vol.36, issue.5, pp.765-770, 1994.

G. Pezzoli, C. Ferrante, S. Barbieri, A. Zecchinelli, and V. Foà, PARKINSONISM DUE TO n-HEXANE EXPOSURE, The Lancet, vol.334, issue.8667, p.874, 1989.

D. Caparros-lefebvre and A. Elbaz, Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study, The Lancet, vol.354, issue.9175, pp.281-286, 1999.

A. E. Lang and A. M. Lozano, Parkinson's Disease, New England Journal of Medicine, vol.339, issue.16, pp.1130-1143, 1998.

J. W. Langston, The parkinson's complex: Parkinsonism is just the tip of the iceberg, Annals of Neurology, vol.59, issue.4, pp.591-596, 2006.

W. Dauer and S. Przedborski, Parkinson's Disease, Neuron, vol.39, issue.6, pp.889-909, 2003.

J. Bové, C. Zhou, V. Jackson-lewis, J. Taylor, Y. Chu et al., Proteasome inhibition and Parkinson's disease modeling, Annals of Neurology, vol.60, issue.2, pp.260-264, 2006.

P. P. Michel, E. C. Hirsch, and S. Hunot, Understanding Dopaminergic Cell Death Pathways in Parkinson Disease, Neuron, vol.90, issue.4, pp.675-691, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01348875

A. J. Espay, L. V. Kalia, Z. Gan-or, C. H. Williams-gray, P. L. Bedard et al., Disease modification and biomarker development in Parkinson disease, Neurology, vol.94, issue.11, pp.481-494, 2020.

D. G. Hernandez, X. Reed, and A. B. Singleton, Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance, Journal of Neurochemistry, vol.139, issue.1, pp.59-74, 2016.

K. J. Billingsley, S. Bandres-ciga, S. Saez-atienzar, and A. B. Singleton, Genetic risk factors in Parkinson?s disease, Cell and Tissue Research, vol.373, issue.1, pp.9-20, 2018.

A. Singleton and J. Hardy, The Evolution of Genetics: Alzheimer?s and Parkinson?s Diseases, Neuron, vol.90, issue.6, pp.1154-1163, 2016.

S. B. Larsen, Z. Hanss, and R. Krüger, The genetic architecture of mitochondrial dysfunction in Parkinson?s disease, Cell and Tissue Research, vol.373, issue.1, pp.21-37, 2018.

T. A. Manolio, F. S. Collins, N. J. Cox, D. B. Goldstein, L. A. Hindorff et al., Finding the missing heritability of complex diseases, Nature, vol.461, issue.7265, pp.747-753, 2009.

A. Elbaz, L. Carcaillon, S. Kab, and F. Moisan, Epidemiology of Parkinson's disease, Revue Neurologique, vol.172, issue.1, pp.14-26, 2016.

A. Elbaz, J. Clavel, P. J. Rathouz, F. Moisan, J. Galanaud et al., Professional exposure to pesticides and Parkinson disease, Annals of Neurology, vol.66, issue.4, pp.494-504, 2009.

C. M. Tanner, G. W. Ross, S. A. Jewell, R. A. Hauser, J. Jankovic et al., Occupation and Risk of Parkinsonism, Archives of Neurology, vol.66, issue.9, pp.1106-1113, 2009.

G. Van-maele-fabry, P. Hoet, F. Vilain, and D. Lison, Occupational exposure to pesticides and Parkinson's disease: A systematic review and meta-analysis of cohort studies, Environment International, vol.46, pp.30-43, 2012.

F. J. Vingerhoets, B. J. Snow, J. W. Tetrud, J. W. Langston, M. Schulzer et al., Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions, Annals of Neurology, vol.36, issue.5, pp.765-770, 1994.

G. Pezzoli, C. Ferrante, S. Barbieri, A. Zecchinelli, and V. Foà, PARKINSONISM DUE TO n-HEXANE EXPOSURE, The Lancet, vol.334, issue.8667, p.874, 1989.

D. Caparros-lefebvre and A. Elbaz, Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study, The Lancet, vol.354, issue.9175, pp.281-286, 1999.

M. A. Hernán, B. Takkouche, F. Caamaño-isorna, and J. J. Gestal-otero, A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease, Annals of Neurology, vol.52, issue.3, pp.276-284, 2002.

K. Parain, C. Hapdey, E. Rousselet, V. Marchand, B. Dumery et al., Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin, Brain Research, vol.984, issue.1-2, pp.224-232, 2003.

J. J. Gagne and M. C. Power, Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis, Neurology, vol.74, issue.12, pp.995-1002, 2010.

R. B. Postuma, W. Poewe, I. Litvan, S. Lewis, A. E. Lang et al., Validation of the MDS clinical diagnostic criteria for Parkinson's disease, Movement Disorders, vol.33, issue.10, pp.1601-1608, 2018.

D. Berg, Validation of the MDS clinical diagnostic criteria for Parkinson's disease, Mov Disord, vol.33, pp.1601-1608, 2018.

D. Berg, C. H. Adler, B. R. Bloem, P. Chan, T. Gasser et al., Movement disorder society criteria for clinically established early Parkinson's disease, Movement Disorders, vol.33, issue.10, pp.1643-1646, 2018.

K. Marek, J. Seibyl, S. Eberly, D. Oakes, I. Shoulson et al., Longitudinal follow-up of SWEDD subjects in the PRECEPT Study, Neurology, vol.82, issue.20, pp.1791-1797, 2014.

A. Antonini and R. Biundo, Can dopamine transporter imaging define early PD?, Nature Reviews Neurology, vol.10, issue.8, pp.432-433, 2014.

C. Marras, P. Rochon, and A. E. Lang, Predicting Motor Decline and Disability in Parkinson Disease, Archives of Neurology, vol.59, issue.11, p.1724, 2002.

B. Post, M. P. Merkus, R. J. De-haan, and J. D. Speelman, Prognostic factors for the progression of Parkinson's disease: A systematic review, Movement Disorders, vol.22, issue.13, pp.1839-1851, 2007.

T. A. Mestre, S. Eberly, C. Tanner, D. Grimes, A. E. Lang et al., Reproducibility of data-driven Parkinson's disease subtypes for clinical research, Parkinsonism & Related Disorders, vol.56, pp.102-106, 2018.

M. Luz, A. Whone, N. Bassani, R. K. Wyse, G. T. Stebbins et al., The Parkinson?s Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures, Brain Communications, vol.2, issue.2, p.46, 2020.

R. De-la-fuente-fernández, M. Schulzer, L. Kuramoto, J. Cragg, N. Ramachandiran et al., Agespecific progression of nigrostriatal dysfunction in Parkinson's disease, Ann Neurol, vol.69, pp.803-813, 2011.

J. M. Fearnley and A. J. Lees, AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY, Brain, vol.114, issue.5, pp.2283-2301, 1991.

H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger, Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations, Journal of the Neurological Sciences, vol.20, issue.4, pp.415-455, 1973.

H. Braak, D. Tredici, K. Rüb, U. De-vos, R. A. et al., Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, vol.24, pp.197-211, 2003.

M. Selikhova, D. R. Williams, P. A. Kempster, J. L. Holton, T. Revesz et al., A clinicopathological study of subtypes in Parkinson's disease, Brain, vol.132, pp.2947-57, 2009.

D. Berg and R. B. Postuma, From Prodromal to Overt Parkinson?s Disease: Towards a New Definition in the Year 2040, Journal of Parkinson's Disease, vol.8, issue.s1, pp.S19-S23, 2018.

E. Tolosa and D. Vilas, Peripheral synuclein tissue markers: a step closer to Parkinson?s disease diagnosis: Figure 1, Brain, vol.138, issue.8, pp.2120-2122, 2015.

A. J. Noyce, A. Lees, and A. E. Schrag, The prediagnostic phase of Parkinson's disease, J Neurol Neurosurg Psychiatry, vol.87, pp.871-879, 2016.

B. Mollenhauer, C. J. Caspell-garcia, C. S. Coffey, P. Taylor, A. Singleton et al., Longitudinal analyses of cerebrospinal fluid ?-Synuclein in prodromal and early Parkinson's disease, Mov Disord, vol.34, pp.1354-1364, 2019.

J. H. Kordower, C. W. Olanow, and H. B. Dodiya, Disease duration and the integrity of the nigrostriatal system in Parkinson's disease, Brain, vol.136, pp.2419-2431, 2013.

A. J. Espay, P. Brundin, and A. E. Lang, Precision medicine for disease modification in Parkinson disease, Nat Rev Neurol, vol.13, pp.119-126, 2017.

H. Braak, U. Rub, W. P. Gai, D. Tredici, and K. , Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen, J Neural Trans, vol.110, pp.517-536, 2003.

A. E. Lang and A. J. Espay, Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations, Mov Disord, vol.33, pp.660-677, 2018.

O. Rascol, Disease-modification" trials in Parkinson disease: target populations, endpoints and study design, Neurology, vol.72, issue.7, pp.51-58, 2009.

C. J. Van-der-schyf, Rational drug discovery design approaches for treating Parkinson's disease, Expert Opin Drug Discov, vol.10, pp.713-741, 2015.

L. Thibault, O. Rascol, J. C. Corvol, J. Ferreira, L. Defebvre et al., New perspectives on study designs for evaluating neuroprotection in Parkinson's disease, Movement Disorders, vol.32, issue.10, pp.1365-1370, 2017.

G. Arribarat and P. Péran, Quantitative MRI markers in Parkinson's disease and parkinsonian syndromes, Current Opinion in Neurology, vol.33, issue.2, pp.222-229, 2020.

T. Eckert, C. Tang, and D. Eidelberg, Assessment of the progression of Parkinson's disease: a metabolic network approach, The Lancet Neurology, vol.6, issue.10, pp.926-932, 2007.

L. V. Kalia, A. E. Lang, and L. N. Hazrati, Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease, JAMA Neurol, vol.72, pp.100-105, 2015.

L. Parkkinen, S. S. O'sullivan, C. Collins, A. Petrie, J. L. Holton et al., Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease, Journal of Parkinson's Disease, vol.1, issue.3, pp.277-286, 2011.

L. Patterson, S. P. Rushton, J. Attems, A. J. Thomas, and C. M. Morris, Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders, Brain Pathology, vol.29, pp.544-557, 2019.

D. J. Irwin, M. Grossman, and D. Weintraub, Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis, Lancet Neurol, vol.16, pp.55-65, 2017.

A. S. Buchman, L. Yu, R. S. Wilson, S. E. Leurgans, S. Nag et al., Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies, Neurology, vol.92, issue.16, pp.e1821-e1830, 2019.

N. P. Visanji, A. E. Lang, and G. G. Kovacs, Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities, Translational Neurodegeneration, vol.8, issue.1, p.28, 2019.

A. J. Espay, J. A. Vizcarra, L. Marsili, A. E. Lang, S. P. Sardi et al., Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases, Neurology, vol.94, issue.3, pp.144-145, 2020.

L. Galluzzi and I. Vitale, Oncogene-induced senescence and tumour control in complex biological systems, Cell Death & Differentiation, vol.25, issue.6, pp.1005-1006, 2018.

D. Van, B. Gouel, F. Jonneaux, A. Timmerman, K. Gelé et al., Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC, Neurobiol Dis, vol.94, pp.169-78, 2016.

S. J. Guiney, P. A. Adlard, A. I. Bush, D. I. Finkelstein, and S. Ayton, Ferroptosis and cell death mechanisms in Parkinson's disease, Neurochemistry International, vol.104, pp.34-48, 2017.

T. I. Kam, X. Mao, H. Park, S. C. Chou, S. S. Karuppagounder et al., Poly(ADP-ribose) drives pathologic ?-synuclein neurodegeneration in Parkinson?s disease, Science, vol.362, issue.6414, p.eaat8407, 2018.

. Poly, ADP-ribose) drives pathologic ?-synuclein neurodegeneration in Parkinson's disease, Science, vol.362, issue.6414, p.8407, 2018.

Z. Wu, Y. Geng, X. Lu, Y. Shi, G. Wu et al., Chaperone-mediated autophagy is involved in the execution of ferroptosis, Proceedings of the National Academy of Sciences, vol.116, issue.8, pp.2996-3005, 2019.

Y. Liu, Y. Wang, J. Liu, R. Kang, and D. Tang, Interplay between MTOR and GPX4 signaling modulates autophagy-dependent ferroptotic cancer cell death, Cancer Gene Therapy, 2020.

G. U. Höglinger, G. Carrard, P. P. Michel, F. Medja, A. Lombès et al., Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease, Journal of Neurochemistry, vol.86, issue.5, pp.1297-1307, 2003.

T. A. Yacoubian and D. G. Standaert, Targets for neuroprotection in Parkinson's disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1792, issue.7, pp.676-687, 2009.

A. Slanzi, G. Iannoto, B. Rossi, E. Zenaro, and G. Constantin, In vitro Models of Neurodegenerative Diseases, Frontiers in Cell and Developmental Biology, vol.8, p.328, 2020.

M. A. Cenci and A. Björklund, Animal models for preclinical Parkinson's research: An update and critical appraisal, Progress in Brain Research, vol.252, pp.27-59, 2020.

P. M. Carvey, Q. Chang, J. W. Lipton, and Z. Ling, Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long term losses of dopamine neurons in offspring a potential new model of parkinson s disease, Frontiers in Bioscience, vol.8, issue.6, pp.s826-837, 2003.

B. Kolb and G. C. Teskey, Age, experience, injury, and the changing brain, Developmental Psychobiology, vol.54, issue.3, pp.311-325, 2010.

J. J. Park, E. Siden, M. J. Zoratti, L. Dron, O. Harari et al., Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols, Trials, vol.20, issue.1, p.572, 2019.

M. L. Zeissler, V. Li, M. K. Parmar, and C. B. Carroll, Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson?s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer, Journal of Parkinson's Disease, vol.10, issue.2, pp.413-428, 2020.

C. W. Olanow, R. A. Hauser, J. Jankovic, W. Langston, A. Lang et al., A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics, Movement Disorders, vol.23, issue.15, pp.2194-2201, 2008.

P. Odin, K. R. Chaudhuri, J. Volkmann, A. Antonini, A. Storch et al., Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson?s disease, npj Parkinson's Disease, vol.4, issue.1, p.14, 2018.

B. A. Faucheux, Y. Agid, E. C. Hirsch, and A. M. Bonnet, Blood vessels change in the mesencephalon of patients with Parkinson's disease, The Lancet, vol.353, issue.9157, pp.981-982, 1999.

C. Barcia, V. Bautista, Á. Sánchez-bahillo, E. Fernández-villalba, B. Faucheux et al., Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian, Journal of Neural Transmission, vol.112, issue.9, pp.1237-1248, 2005.

K. E. Ohlin, I. Sebastianutto, C. E. Adkins, C. Lundblad, P. R. Lockman et al., Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease, NeuroImage, vol.61, issue.1, pp.228-239, 2012.

P. C. Pires and A. O. Santos, Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies, Journal of Controlled Release, vol.270, pp.89-100, 2018.

F. Dholkawala, C. Voshavar, and A. K. Dutta, Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson?s disease, European Journal of Pharmaceutics and Biopharmaceutics, vol.103, pp.62-70, 2016.

J. V. Georgieva, D. Hoekstra, and I. S. Zuhorn, Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood?Brain Barrier, Pharmaceutics, vol.6, issue.4, pp.557-583, 2014.

A. Gaudin, M. Yemisci, H. Eroglu, S. Lepetre-mouelhi, O. F. Turkoglu et al., Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury, Nature Nanotechnology, vol.9, issue.12, pp.1054-1062, 2014.

L. Mursaleen, B. Noble, S. H. Chan, S. Somavarapu, and M. G. Zariwala, N-Acetylcysteine Nanocarriers Protect against Oxidative Stress in a Cellular Model of Parkinson?s Disease, Antioxidants, vol.9, issue.7, p.600, 2020.

Q. He, J. Liu, J. Liang, X. Liu, W. Li et al., Towards Improvements for Penetrating the Blood?Brain Barrier?Recent Progress from a Material and Pharmaceutical Perspective, Cells, vol.7, issue.4, p.24, 2018.

M. J. Hasnat and J. E. Rice, Intrathecal baclofen for treating spasticity in children with cerebral palsy, Cochrane Database of Systematic Reviews, vol.11, p.4552, 2015.

G. Paul, O. Zachrisson, A. Varrone, P. Almqvist, M. Jerling et al., Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson?s disease patients, Journal of Clinical Investigation, vol.125, issue.3, pp.1339-1346, 2015.

A. Burgess, K. Shah, O. Hough, and K. Hynynen, Focused ultrasound-mediated drug delivery through the blood?brain barrier, Expert Review of Neurotherapeutics, vol.15, issue.5, pp.477-491, 2015.

L. Floc, &. , J. Lu, H. D. Lim, T. L. Démoré et al.,

J. Le-floc?h, H. D. Lu, T. L. Lim, C. Démoré, R. K. Prud?homme et al., Transcranial Photoacoustic Detection of Blood-Brain Barrier Disruption Following Focused Ultrasound-Mediated Nanoparticle Delivery, Molecular Imaging and Biology, vol.22, issue.2, pp.324-334, 2019.

M. Dickson and J. P. Gagnon, Key factors in the rising cost of new drug discovery and development, Nature Reviews Drug Discovery, vol.3, issue.5, pp.417-429, 2004.

D. Devos, C. Moreau, J. C. Devedjian, J. Kluza, M. Petrault et al., Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease, Antioxidants & Redox Signaling, vol.21, issue.2, pp.195-210, 2014.

C. Moreau, J. A. Duce, O. Rascol, J. C. Devedjian, D. Berg et al., Iron as a therapeutic target for Parkinson's disease, Movement Disorders, vol.33, issue.4, pp.568-574, 2018.

, Mov Disord, vol.33, pp.568-574, 2018.

K. Mcfarthing, S. Buff, .. G. Rafaloff, T. Dominey, R. Wyse et al., Parkinson's disease drug therapies in the clinical trial pipeline: 2020, J Parkinsons Dis, vol.10, pp.757-774, 2020.